A Partially Blinded, Single-dose, Cross-over Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide (Positive Control) and Placebo in Mild-to-moderate COPD Patients.
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2011
At a glance
- Drugs QAX 028; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacodynamics
- 01 Mar 2010 Planned number of patients changed from 36 to 36.
- 10 Mar 2008 Status changed from recruiting to completed.
- 20 Dec 2007 New trial record.